CME Group Dividends and Buybacks
Dividend criteria checks 4/6
CME Group is a dividend paying company with a current yield of 4.19% that is well covered by earnings. Next payment date is on 25th September, 2026 with an ex-dividend date of 9th September, 2026.
Key information
4.2%
Dividend yield
1.6%
Buyback Yield
| Total Shareholder Yield | 5.8% |
| Future Dividend Yield | 4.6% |
| Dividend Growth | 8.4% |
| Next dividend pay date | 25 Sep 26 |
| Ex dividend date | 09 Sep 26 |
| Dividend per share | n/a |
| Payout ratio | 43% |
Recent dividend and buyback updates
Recent updates
Seeking Alpha • Aug 13
CME Group: 'Buy' The Market's Infrastructure
Summary CME Group operates as the world's leading derivatives marketplace, serving as essential infrastructure for stock and fixed income markets. CME benefits from interest rate volatility, proprietary benchmark products, and a high-margin, recurring revenue model with 33 consecutive quarters of market data growth. Shares trade at a forward P/E of 21.8, a 9% discount to a $290 fair value estimate; consensus expects 7.5% annual EPS growth through 2028. Risks include periods of market calm compressing volumes and potential competition from OTC platforms, but CME's dominant position and dividend growth remain compelling. Read the full article on Seeking Alpha
Narrative Update • Jul 28
CME: Perpetual Futures Dispute And New Contracts Will Shape Earnings Profile
The analyst fair value estimate for CME Group has been trimmed by about $6.64 to $282.36, as analysts balance slightly higher projected revenue growth with lower profit margin assumptions and a modestly reduced future P/E multiple following a mix of recent target cuts and increases across the Street. Analyst Commentary Recent research on CME Group shows a split view, with some firms lifting price targets and ratings while others trim expectations and flag competitive threats.Narrative Update • Jul 09
CME: Crypto Perpetual Futures Dispute Will Reshape Long Term Earnings Power
The analyst price target for CME Group has been trimmed by about $14 to reflect slightly softer revenue growth assumptions, a modestly higher discount rate, and lower future P/E multiples that many analysts link to competitive concerns around perpetual futures, despite broadly constructive views on the core franchise. Analyst Commentary Recent research on CME Group highlights a split view, with some analysts seeing attractive upside after the share pullback and others focusing on competitive threats and pricing pressure.Narrative Update • Jun 24
CME: Crypto Perpetual Futures Dispute Will Shape Future Earnings Power
The analyst price target for CME Group has shifted slightly lower, with fair value moving from about $306.47 to $302.60 as analysts weigh ongoing concerns around perpetual futures and potential multiple compression against views that recent share weakness and structural demand drivers still support an attractive long term setup. Analyst Commentary Recent research on CME Group shows a split between bullish analysts who see the recent pullback and product portfolio as supportive for long term value, and more cautious voices focused on competitive threats from perpetual futures and the potential impact on valuation multiples.Analysis Article • Jun 18
CME Group (CME) Stock Could Be 18% Undervalued After CEO Succession News
CME Group (CME) stock is in focus after the company confirmed a leadership transition that will see long time Chairman and CEO Terry Duffy move to Executive Chairman while President and CFO Lynne Fitzpatrick becomes CEO in 2027. See our latest analysis for CME Group. The leadership announcement landed against a weaker backdrop for CME Group stock, with the share price down 3.46% over the past day and 17.23% over the past 30 days, while the 5 year total shareholder return of 45.07% still...Narrative Update • Jun 05
CME: Crypto And AI Futures Expansion Will Shape Future Earnings Power
Analysts have trimmed their average price target for CME Group to about $306.47. This reflects concerns that revenue momentum could soften as geopolitical volatility eases and that fresh competition in bitcoin perpetual futures may weigh on exchange valuations, even as several firms still see the competitive risk as manageable.Narrative Update • May 15
CME: Mixed Street Views And New Markets Will Shape Future Earnings Power
Narrative Update on CME Group The analyst price target for CME Group has been trimmed by about $2, reflecting updated views on slightly softer revenue growth and a modestly lower future P/E multiple. At the same time, some analysts highlight areas of support such as commodities volumes as well as agriculture and prediction markets.Narrative Update • Apr 27
CME: Volatile Street Views And New Futures Will Shape Trading Mix
Analysts have nudged their fair value estimate for CME Group down to $308.20 from $311.67, reflecting slightly softer revenue growth assumptions and a higher discount rate, partly balanced by a higher projected profit margin and a modestly lower future P/E, in line with the mix of recent price target trims and increases across the Street. Analyst Commentary Recent Street research on CME Group has been active on both sides, with several firms adjusting price targets and ratings in different directions.Narrative Update • Apr 11
CME: Volatility And New Contracts Will Shape Rare Earths And Crypto Volumes
The updated analyst price target for CME Group has moved higher by about $5 to $311.67. This change reflects analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a marginally higher future P/E multiple, even as they factor in a small trim to projected profit margins.Narrative Update • Mar 26
CME: Volatility And New Contracts Will Shape Rare Earths And Volume Mix
Analysts have made a modest upward adjustment to the CME Group fair value estimate to about $307 from roughly $305, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin, and future P/E following a mix of recent rating changes and price target tweaks across the Street. Analyst Commentary Recent research on CME Group reflects a mixed but generally balanced backdrop, with several firms adjusting ratings and price targets in different directions.Narrative Update • Mar 11
CME: Volatility And New Contracts Will Shape Rare Earths And Clearing Outlook
Our analyst price target for CME Group has moved modestly higher to $305.21 from $299.29, as analysts factor in slightly stronger modeled revenue growth and profitability. This is partially offset by a more conservative future P/E assumption and mixed views on volume drivers across product lines.Narrative Update • Feb 25
CME: Volatility And New Contracts Will Shape Futures And Clearing Outlook
The analyst price target for CME Group edges higher to $232, with recent updates reflecting analysts' focus on firmer commodities volumes, as well as a more expense conscious outlook in their refreshed earnings models. Analyst Commentary Recent Street research around CME Group reflects a mix of optimism on volumes and earnings power, alongside caution on valuation and the cost base.Narrative Update • Feb 10
CME: Volatility And Prediction Markets Will Guide Futures And Clearing Expansion Outlook
The updated analyst price target for CME Group edges higher to about US$297 from roughly US$290, reflecting analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a similar future P/E multiple despite a slightly lower profit margin input. Analyst Commentary Street research on CME Group in recent sessions centers on a cluster of revised price targets and at least one rating change, with several bullish analysts lifting their targets by varying dollar amounts and one major bank fine tuning its view in both directions over a short time frame.Narrative Update • Jan 27
CME: Volatility And Prediction Markets Will Shape Futures Activity Outlook
The analyst price target for CME Group is now US$290.40, a move of about US$2 from the prior US$288.33, as analysts factor in slightly different assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E following mixed recent research that includes both a modest target cut and an upgrade linked to a tilt toward volatility. Analyst Commentary Recent research on CME Group reflects a mix of optimism and caution, with one firm trimming its price target slightly and another upgrading the stock on what it sees as a better setup for volatility related trading activity.Narrative Update • Jan 12
CME: Fee Moat And Prediction Markets Will Shape Futures Activity Outlook
Narrative Update: CME Group CME Group's fair value estimate has edged up by about $1 to roughly $288 per share, as analysts cite the company's strong futures and options moat, a higher price target range of up to $314, and interest in its role within prediction markets as key supports for the updated outlook. Analyst Commentary Recent Street research has been generally constructive on CME Group, with several bullish analysts adjusting their price targets higher and highlighting the company's futures and options franchise as a key support for valuation.Narrative Update • Dec 27
CME: Fee Resilience And Prediction Markets Will Balance Lower Volatility Risks
Analysts have nudged their average price target on CME Group modestly higher, to approximately $287 from about $286, citing the company’s resilient fee-based revenue mix, strong competitive moat in futures and options, and supportive demand signals from prediction market partnerships despite some conflicting views on near term volume volatility. Analyst Commentary Recent Street research presents a mixed but generally constructive view on CME Group, with upward moves in price targets tempered by concerns around volume sensitivity and valuation risk if volatility normalizes.Narrative Update • Dec 13
CME: Fee Resilience And New Prediction Markets Will Help Navigate Volatility
Analysts have raised their fair value estimate for CME Group by about $1 to roughly $286 per share, citing the company’s resilient clearing and transaction fee driven revenue base, modestly higher long term growth expectations, and a reinforced competitive moat highlighted in recent target revisions across the Street. Analyst Commentary Street research on CME Group reflects a wide range of views on valuation and execution, with recent target changes clustering around expectations for resilient fee income but diverging on the sustainability of growth and the impact of lower volatility.Narrative Update • Nov 16
CME: Revenue Resilience And New Ventures Will Balance Volatility Risks Ahead
The average analyst price target for CME Group was raised by approximately $3 to $285, as analysts point to the firm's resilient revenue streams and strong market position amid continued macroeconomic uncertainty. Analyst Commentary Recent analyst activity reflects a mix of optimism and caution regarding CME Group's performance and outlook, particularly as the firm navigates shifting macroeconomic and market conditions.Upcoming Dividend Payment
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: CME's dividend payments have been volatile in the past 10 years.
Growing Dividend: CME's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| CME Group Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (CME) | 4.2% |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.0% |
| Industry Average (Capital Markets) | 2.0% |
| Analyst forecast (CME) (up to 3 years) | 4.6% |
Notable Dividend: CME's dividend (4.19%) is higher than the bottom 25% of dividend payers in the US market (1.33%).
High Dividend: CME's dividend (4.19%) is in the top 25% of dividend payers in the US market (3.99%)
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (43%), CME's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (96.9%), CME's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/21 03:40 |
| End of Day Share Price | 2026/08/20 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CME Group Inc. is covered by 32 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephen Biggar | Argus Research Company |
| Benjamin Budish | Barclays |
| Roger Freeman | Barclays |